Secure CheckoutPersonal information is secured with SSL technology.
Free ShippingFree global shipping
No minimum order.
Bioreduction in the Activation of Drugs covers the proceedings of the Second Biochemical Pharmacology Symposium. The book presents papers that cover the applications of bioreduction in drug activation, along with its concerns. The text first presents materials about enzymology, such as overview of enzyme systems involved in bioreduction of drugs and in redox cycling, and reductive role of glutathione in the redox cycling of oxidizable drugs. Next, the book covers papers on bacterial and parasites infection, which include reduction by the gut microflora of animals and human and reduction of nitroimidazoles in vitro and DNA damage. The remaining articles deal with cancer treatment, such as hypoxia-mediated nitro-heterocyclic drugs in the radio- and chemotherapy of cancer, and the biological properties of reduced nitroheterocyclics and possible underlying biochemical mechanisms. The text will be of great use to researchers and practitioners of medicine, pharmacology, and biochemistry.
Session A: Enzymology
Overview of Enzyme Systems Involved in Bioreduction of Drugs and in Redox Cycling
Regulation of Reductive Processes by Glutathione
The Crucial Role of Low Steady State Oxygen Partial Pressures in Haloalkane Free-Radical-Mediated Lipid Peroxidation. Possible Implications in Haloalkane Liver Injury
Reductive Role of Glutathione in the Redox Cycling of Oxidizable Drugs
Generation of Photoemissive Species During Quinone Redox Cycling
Session B: Bacterial and Parasite Infections
Reduction by the Gut Microflora of Animals and Man
The Metabolic Activation of Ronidazole[(L-Methyl-5-Nitroimidazole- 2-Yl)-Methyl Carbamate] to Reactive Metabolites by Mammalian, Cecal Bacterial and T. Foetus Enzymes
Reductive Activation of Nitroimidazoles in Anaerobic Microorganisms
Comparing the Reduction of Nitroimidazoles in Bacteria and Mammalian Tissues and Relating it to Biological Activity
Reduction of Nitroimidazoles in Vitro and DNA Damage
In Vitro Reductive Activation of Nitroimidazoles
Inhibition of Hydrogen Production in Drug-Resistant and Susceptible Trichomonas Vaginalis Strains by a Range of Nitroimidazole Derivatives
The Role of the Gut Flora in the Reduction of Sulphoxide Containing Drugs
Session C: Role in Treatment of Cancer—Part I
The Role of Mitomycin Antibiotics in the Chemotherapy of Solid Tumors
Hypoxia-Mediated Nitro-Heterocyclic Drugs in the Radioand Chemotherapy of Cancer. An Overview
Biochemistry Of Reduction of Nitro Heterocycles Short Communications
Toxicity of Oxygen at Atmospheric Concentration for Newly Explanted Cancer Cells
The Effect of Bioreduction on the Oncogenicity of Nitroimidazoles
Session D: Role in Treatment of Cancer—Part II
The Biological Properties of Reduced Nitroheterocyclics and Possible Underlying Biochemical Mechanisms
RSU 1069, A Nitroimidazole Containing an Aziridine Group. Bioreduction Greatly Increases Cytotoxicity Under Hypoxic Conditions
Sensitization of Cancer Chemotherapeutic Agents by Nitroheterocyclics
Benznidazole: Nitroreduction and Inhibition of Cytochrome P-450 in Chemosensitization of Tumour Response to Cytotoxic Drugs
- No. of pages:
- © Pergamon 1986
- 1st January 1986
- eBook ISBN:
Elsevier.com visitor survey
We are always looking for ways to improve customer experience on Elsevier.com.
We would like to ask you for a moment of your time to fill in a short questionnaire, at the end of your visit.
If you decide to participate, a new browser tab will open so you can complete the survey after you have completed your visit to this website.
Thanks in advance for your time.